-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test is an affordable, accessible blood test that detects cancer in dogs.
Shallow Nanopore sequencing reveals genomic and epigenomic signatures of circulating tumor DNA in neuroendocrine tumor patients
- Share
- Tweet
- Share on Facebook
- Share
Poster titled: Prognostic Value of Circulating H3K27Me3-Nucleosomes In Newly Diagnosed Lung Cancer Patients
Benjamin P. Berman, Maria Ouzounova, Marie Piecyk, Christina Wheeler, Theresa K. Kelly, Lea Payen-Gay, Thomas Walter
Presented at CNAPS 2025
Related Articles
-
Poster & Publications
Background DNA methylation Changes in Chromatin Released During Neutrophil Extracellular Trap (NET) Formation as Part of the Immune Response
-
Videos
Video: Direct analysis of transcription factor protected cfDNA in plasma by ChIP-seq: Measurement of altered CTCF binding in cancer is a novel biomarker for liquid biopsy
- Share
- Tweet
- Share on Facebook
- Share
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields